Global Tardive Dyskinesia Therapeutics Market Size Study & Forecast, by Drug (Deutetrabenazine, Valbenazine, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies), and Regional Analysis, 2023-2030

Global Tardive Dyskinesia Therapeutics Market Size Study & Forecast, by Drug (Deutetrabenazine, Valbenazine, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies), and Regional Analysis, 2023-2030

Global Tardive Dyskinesia Therapeutics Market is valued at approximately USD 2.33 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 9.1% over the forecast period 2023-2030. Tardive Dyskinesia (TD) therapeutics refer to treatments aimed at managing the symptoms of TD, a drug-induced movement disorder characterized by involuntary movements of the tongue, face, trunk, and extremities. These therapies primarily focus on improving the motor symptoms associated with TD, which can significantly impact patients' quality of life. The support of TD treatment involves the use of medications such as valbenazine (INGREZZA) and deutetrabenazine (AUSTEDO), both of which are VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors). These drugs help regulate dopamine levels in the brain, thereby reducing abnormal movements caused by TD. Additionally, patients benefit from other supportive therapies, including physical therapy, occupational therapy, and speech therapy, aimed at improving motor control and functional abilities. Treatment plans for TD are often tailored to individual patient needs and may involve a combination of pharmacological and non-pharmacological interventions. The Tardive Dyskinesia Therapeutics Market is expanding because of factors such as the increasing prevalence of tardive dyskinesia, growing antipsychotic prescriptions, advancements in drug development, and increasing recognition and acceptance of mental health issues worldwide.

In addition, the rising government initiatives aimed at raising awareness about this disorder is poised to acts as a catalyzing factor for market growth across the globe. Numerous countries have initiated government-sponsored programs designed to educate both the public and healthcare professionals about the causes, symptoms, and available treatment options for this condition. For instance, in May 2022, the U.S. government spearheaded Tardive Dyskinesia Awareness Week during the first full week of May. This nationwide awareness campaign engaged all 50 states and the District of Columbia, fostering a deeper understanding of this often-misunderstood orphan disease. Through collaborative efforts, the U.S. government sought to advocate for approximately 600,000 individuals in the U.S. affected by this condition. The upsurge in government initiatives is anticipated to propel market growth during the estimated period. Moreover, the increase in initiatives to boost patient engagement by innovative campaigns, as well as the growing emphasis on investing in research and development present various lucrative opportunities over the forecast years. However, the introduction of alternative options to these medications and the side effects associated with tardive dyskinesia therapeutics are hampering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Tardive Dyskinesia Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing aging population, high prevalence of schizophrenia, increasing awareness, increasing healthcare expenditure, and the presence of well-established healthcare infrastructure. Whereas, Europe is expected to grow at the highest CAGR over the forecast years. The increasing research and development activities, supportive regulatory frameworks and expedited approvals for new therapies, and rising prevalence of this condition across the region, which will lead to the increase in demand for its treatment. According to a research paper published by the journal Psychiatry and Clinical Neurosciences in August 2022, the prevalence of TD was estimated at 23.3% in Europe. This offers a lucrative opportunity for the market players to launch novel products during the forecast period.

Major market players included in this report are:
Teva Pharmaceutical Industries Ltd
Neurocrine Biosciences, Inc
Sun Pharmaceutical Industries Ltd
SteriMax Inc.
Adamas Pharmaceuticals, Inc
Sanis
AbbVie Inc.
Mylan N.V,
Reddy's Laboratories Ltd,
Sun Pharmaceutical Industries Ltd

Recent Developments in the Market:
 In May 2022, Neurocrine Biosciences unveiled groundbreaking findings on the effectiveness of INGREZZA (valbenazine) in enhancing tardive dyskinesia management and maintaining psychiatric symptom stability during the American Psychiatric Association Annual Meeting 2022.
 In March 2022, Mitsubishi Tanabe Pharma Corporation received regulatory approval from the Ministry of Health, Labor, and Welfare for the use of DYSVAL capsules 40mg as a treatment for tardive dyskinesia. DYSVAL is a vesicular monoamine transporter type 2 (VMAT2) inhibitor.
 In December 2021, Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical K.K. forged a co-promotion agreement for MT-5199, a vesicular monoamine transporter type 2 (VMAT2) inhibitor designated for treating tardive dyskinesia in Japan.

Global Tardive Dyskinesia Therapeutics Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Drug, Distribution Channel, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug:
Deutetrabenazine
Valbenazine
Others

By Distribution Channel:
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.